Heel displaced intra-articular fractures treated with mini-calcaneal external fixator.

INTRODUCTION: Treatment of displaced heel fractures is controversial; however, ORIF is widely described in the literature to be the gold-standard. Percutaneous reduction and monolateral external fixation is gaining increasing attention because it provides a good and stable reduction, and minimises soft tissue complications due to open surgery, such as deep infections and delays in wound healing. The aim of this study was to show that the new Orthofix Calcaneal Minifixator (six pins) provides a greater stability than the four-pin version to enable a better and more stable reduction, an earlier weight-bearing (30 days) and improved functional outcomes. METHODS: A series of 69 consecutive closed heel intraarticular displaced fractures treated with the new Orthofix Calcaneal Minifixator were evaluated. Patients were assessed clinically with the Maryland Foot Score and radiologically with standard radiographs. RESULTS: The clinical results at follow-up were excellent in 37 cases (53.6%), good in 27 (39.2%), fair in two (2.9%) and poor in three (4.3%). The mean preoperative Böhler's angle was 5.2˚ (range 0-18˚) and the mean postoperative value was 28.5˚ (range 16-38˚). CONCLUSION: The excellent functional outcomes were despite some radiological images of imperfect posterior facet anatomical reduction and seemed to correlate with the use of a good and stable minimally-invasive surgical technique. This technique enabled early weight-bearing, minimised complications, respected the delicate biology of this anatomical site and restored the good heel volume and Böhler angle.

[Trends in cancer incidence as observed by Lombardy cancer registry, Varese Province]. / Evoluzione nel tempo dell'incidenza misurata dal registro tumori della regione Lombardia in provincia di Varese.

Trends in cancer risk of the Varese province Cancer Registry from 1976 to 1987 have been considered. The analysis has been carried out subdividing the 12 years of observation in three quadriennia. In younger ages (0 to 54) an increase of melanomas, of testicular cancer and, only in females, of tobacco-related cancers (oral cavity, oesophagus, pancreas, larynx, lung, bladder and kidney) has been observed. In younger males, instead, a decrease of tobacco-related cancer risk is already observable. Below age 55 there is no reduction in gastric cancer risk. The increase of breast cancer for youngest women is only observed between the first and the second quadriennium. For older ages (from 55 to 74) tobacco-related cancers continue to increase, in both sexes, but mainly among females. Also increasing, for males, are colon and liver cancer risks. Among the same ages, gastric and cervix (for screened age groups) cancer risks are decreasing. These observations, most in accordance with patterns observed in other western countries, can be used for setting intervention and research priorities.

Survival for lung cancer in northern Italy.

From the population covered by the Lombardy Cancer Registry (northern Italy), all 2,259 lung cancer patients diagnosed from 1976 to 1981 were followed through 30 November 1989. The length of follow-up ranged from eight to 13 years. A special investigation on long-term survivors showed that a negligible proportion (0.01 percent) of errors occur in determining life status when an active follow-up is adopted. Age, stage, and histotype were found to be statistically significant, independent, prognostic factors in multivariate analysis both by the Cox model and by a model considering the relative survival. Observed survival was 29 percent at one year after diagnosis, 13 percent at two years, eight percent at three years, five percent at five years and two percent at 10 years. Survival decreased with age, but the youngest patients of both sexes showed lower survival compared with immediately subsequent ages. Among morphologically confirmed tumors, epidermoid carcinomas and adenocarcinomas showed the highest survival (38 percent and 33 percent at one year, respectively); small cell carcinomas showed the poorest prognosis (one-year survival, 23 percent). Beyond the second year after diagnosis, differences between histotypes became slighter. Survival according to stage showed a decreasing pattern from limited to advanced tumors, one-year figures being 41 percent for localized tumors, 27 percent for regional metastasis, and three percent for distant metastasis. Relative survival in Varese was compared with that reported by other cancer registries in Western countries: the variability noted could be related to different modalities of registration and to different distribution of clinical and demographic factors.